Modelling the cost-effectiveness of adopting risk-stratified approaches to extended screening intervals in the national diabetic retinopathy screening programme in Scotland

Diabetic Medicine

Volumn 33, Issue 7, 2016, Pages 886-895

  Scotland, G ^a,b   McKeigue, P ^c   Philip, S ^d   Leese, G P ^e   Olson, J A ^d   Looker, H C ^f   Colhoun, H M ^f   Javanbakht, M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d NHS GRAMPIAN   (United Kingdom)

^e NHS TAYSIDE   (United Kingdom)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIABETIC RETINOPATHY; DISEASE COURSE; FEMALE; HEALTH CARE COST; HIDDEN MARKOV MODEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; OUTCOME ASSESSMENT; PATIENT RISK; POPULATION; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK FACTOR; SCOTLAND; SCREENING TEST; TIME TO TREATMENT; VISUAL ACUITY;

EID: 84975165637     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.13129     Document Type: Article

References (42)

1. Scottish Diabetic Retinopathy Screening Collaborative. Scottish diabetic retinopathy screening programme annual report 2013–2014. NHS Scotland: Scottish Diabetic Retinopathy Screening Collaborative, 2014. Available at http://www.ndrs-wp.scot.nhs.uk/?page_id=149 Last accessed 10 April 2016.
2. Scottish Diabetes Survey Monitoring Group. Scottish diabetes survey 2011. NHS Scotland, 2011. Available at http://www.diabetesinscotland.org.uk/Publications/SDS%202011.pdf Last accessed 11 April 2016.
3. Leese GP. Should diabetes retinal screening intervals change? Diabet Med 2013; 30: 43–45.
4. Looker HC, Nyangoma SO, Cromie DT, Olson JA, Leese GP, Philip S et al. Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish diabetic retinopathy screening programme. Diabetologia 2013; 56: 1716–1725.
5. UK National Screening Committee. The UK NSC recommendation on diabetic retinopathy screening in adults, 2015. Available at http://legacy.screening.nhs.uk/diabeticretinopathy Last accessed 11 January 2016.
6. Four Nations Diabetic Retinopathy Screening Intervals Project Study Group. Final report of the study group. UK National Screening Committee, 2013. Availabe at http://legacy.screening.nhs.uk/diabeticretinopathy Last accessed 11 April 2016.
7. Taylor-Phillips S, Mistry H, Leslie R, Todkill D, Tsertsvadze A, Connock M et al. Extending the diabetic retinopathy screening interval beyond 1 year: systematic review. Br J Ophthalmol 2015; 100: 105–114.
8. Goatman KA, Philip S, Fleming AD, Harvey RD, Swa KK, Styles C et al. External quality assurance for image grading in the Scottish diabetic retinopathy screening programme. Diabet Med 2012; 29: 776–783.
9. Scottish Diabetic Retinopathy Screening Collaborative. Scottish diabetic retinopathy grading scheme 2007. NHS Scotland: Scottish Diabetic Retinopathy Screening Collaborative, 2007. Available at http://www.ndrs-wp.scot.nhs.uk/wp-content/uploads/2013/04/Grading-Scheme-2007-v1.1.pdf Last accessed 11 April 2016.
10. Jackson C. Multi-State models for panel data: the msm package for R. J Statistical Software 2011; 38: 1–28.
11. Olson J, Sharp P, Goatman K, Prescott G, Scotland G, Fleming A et al. Improving the economic value of photographic screening for optical coherence tomography-detectable macular oedema: a prospective, multicentre, UK study. Health Technol Assess 2013; 17: 1–142.
12. Early Treatment of Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment of Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103: 1796–1806.
13. Early Treatment of Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment of Diabetic Retinopathy Study report no. 4. Int Ophthalmol Clin 1987; 27: 265–272.
14. Scottish Medicines Consortium. Ranibizumab for the treatment of visual impairment due to diabetic macular oedema (DMO). Glasgow: Scottish Medicines Consortium, 2012. Available at https://www.scottishmedicines.org.uk/SMC_Advice/Advice/711_11_ranibizumab_lucentis/ranibizumab_Lucentis_Resubmission Last accessed 11 April 2016.
15. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064–1077, e35.
16. Mitchell P, Annemans L, Gallagher M, Hasan R, Thomas S, Gairy K et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial. Br J Ophthalmol 2012; 96: 688–693.
17. National Institute of Health and Care Excellence. TA 237 Ranibizumab for treating diabetic macular oedema (rapid review of technology appraisal guidance 237). National Institute for Health and Care Excellence, 2013. Available at https://www.nice.org.uk/guidance/ta274/documents/macular-oedema-diabetic-ranibizumab-rapid-review-of-ta237-appraisal-consultation-document Last accessed 11 April 2016.
18. The Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 1976; 81: 383–396.
19. Javitt JC, Aiello LP, Chiang Y, Ferris FL 3rd, Canner JK, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care 1994; 17: 909–917.
20. Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study report #18. Invest Ophthalmol Vis Sci 1998; 39: 233–252.
21. Blankenship GW. Fifteen-year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the diabetic retinopathy study. Ophthalmology 1991; 98: 125–128.
22. Yorston D, Wickham L, Benson S, Bunce C, Sheard R, Charteris D. Predictive clinical features and outcomes of vitrectomy for proliferative diabetic retinopathy. Br J Ophthalmol 2008; 92: 365–368.
23. Office for National Statistics (ONS). National life tables, United Kingdom, 2010–2012. ONS, 2014. Available at http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/bulletins/nationallifetablesunitedkingdom/2014-03-21 Last accessed 11 April 2016.
24. National Diabetes Audit 2011–2012: 2013; Report 2: complications and mortality. The Health and Social Care Information Centre (HSCIC) 2013. Available at http://www.hscic.gov.uk/catalogue/PUB12738 Last accessed 11 April 2016.
25. Department of Health. NHS reference costs 2012 to 2013. Department of Health, 2013. Available at https://www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013 Last accessed 11 April 2016.
26. Curtis L. Unit costs of health and social care. Canterbury; University of Kent, 2013. Available at http://www.pssru.ac.uk/project-pages/unit-costs/2013/ Last accessed 11 April 2016.
27. Joint Formulary Committee Editor. British national formulary 67. London: BNF, 2014.
28. Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol 2003; 87: 1201–1204.
29. Lloyd A, Nafees B, Gavriel S, Rousculp MD, Boye KS, Ahmad A. Health utility values associated with diabetic retinopathy. Diabet Med 2008; 25: 618–624.
30. Philip S, Fleming AD, Goatman KA, Fonseca S, McNamee P, Scotland GS et al. The efficacy of automated ‘disease/no disease' grading for diabetic retinopathy in a systematic screening programme. Br J Ophthalmol 2007; 91: 1512–1517.
31. Scotland GS, McNamee P, Philip S, Fleming AD, Goatman KA, Prescott GJ et al. Cost-effectiveness of implementing automated grading within the national screening programme for diabetic retinopathy in Scotland. Br J Ophthalmol 2007; 91: 1518–1523.
32. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. National Institute for Health and Care Excellence, 2013. Available at https://www.nice.org.uk/article/pmg9/chapter/foreword Last accessed 11 April 2016.
33. Briggs A, Claxton K, Sculpher M, editors. Decision modelling for health economic evaluation. Oxford: Oxford University Press, 2006.
34. Ford JA, Elders A, Shyangdan D, Royle P, Waugh N. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review. BMJ 2012; 345: e5182.
35. Leese GP, Stratton IM, Land M, Bachmann MO, Jones C, Scanlon P et al. Progression of diabetes retinal status within community screening programs and potential implications for screening intervals. Diabetes Care 2015; 38: 488–494.
36. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.
37. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–713.
38. Wong TY, Mwamburi M, Klein R, Larsen M, Flynn H, Hernandez-Medina M et al. Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis. Diabetes Care 2009; 32: 2307–2313.
39. Tung TH, Shih HC, Chen SJ, Chou P, Liu CM, Liu JH. Economic evaluation of screening for diabetic retinopathy among Chinese Type 2 diabetics: a community-based study in Kinmen, Taiwan. J Epidemiol 2008; 18: 225–233.
40. Davies R, Roderick P, Canning C, Brailsford S. The evaluation of screening policies for diabetic retinopathy using simulation. Diabet Med 2002; 19: 762–770.
41. Dasbach EJ, Fryback DG, Newcomb PA, Klein R, Klein BE. Cost-effectiveness of strategies for detecting diabetic retinopathy. Med Care 1991; 29: 20–39.
42. Scanlon PH, Aldington SJ, Leal J, Luengo-Fernandez R, Oke J, Sivaprasad S et al. Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. Health Technol Assess 2015; 19: 1–116.